Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity–data from the EU‐AIR

RD Murray, B Ekman, S Uddin, C Marelli… - Clinical …, 2017 - Wiley Online Library
Context and objective Treatment for adrenal insufficiency (AI) remains suboptimal. Despite
glucocorticoid replacement, patients with AI have reduced life expectancy and quality of life …
被引用次数：64 相关文章
[PDF] academia.edu

[PDF][PDF] Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity–data from the EU-AIR

RD Murray, B Ekman, S Uddin, C Marelli… - Clinical …, 2017 - academia.edu
Context and objective Treatment for adrenal insufficiency (AI) remains suboptimal. Despite
glucocorticoid replacement, patients with AI have reduced life expectancy and quality of life …
[PDF] archive.org

[PDF][PDF] Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity–data from the EU-AIR

RD Murray, B Ekman, S Uddin, C Marelli… - Clinical …, 2017 - scholar.archive.org
Context and objective Treatment for adrenal insufficiency (AI) remains suboptimal. Despite
glucocorticoid replacement, patients with AI have reduced life expectancy and quality of life …

Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity–data from the EU‐AIR

RD Murray, B Ekman, S Uddin, C Marelli… - Clinical …, 2017 - infona.pl
Context and objective Treatment for adrenal insufficiency (AI) remains suboptimal. Despite
glucocorticoid replacement, patients with AI have reduced life expectancy and quality of life …
[PDF] core.ac.uk

[PDF][PDF] Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity–data from the EU-AIR

RD Murray, B Ekman, S Uddin, C Marelli… - Clinical …, 2017 - core.ac.uk
Context and objective Treatment for adrenal insufficiency (AI) remains suboptimal. Despite
glucocorticoid replacement, patients with AI have reduced life expectancy and quality of life …

Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity-data from the EU-AIR.

RD Murray, B Ekman, S Uddin, C Marelli… - Clinical …, 2017 - search.ebscohost.com
Context and objective Treatment for adrenal insufficiency (AI) remains suboptimal. Despite
glucocorticoid replacement, patients with AI have reduced life expectancy and quality of life …

Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity-data from the EU-AIR.

RD Murray, B Ekman, S Uddin, C Marelli… - Clinical …, 2016 - europepmc.org
Results Most patients (87· 4%) were receiving hydrocortisone. The most common dose
range, taken by 42· 2% of patients, was 20 to< 25 mg/day; however, 12· 6% were receiving …

Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity-data from the EU-AIR

RD Murray, B Ekman, S Uddin, C Marelli… - Clinical …, 2017 - discovery.ucl.ac.uk
CONTEXT AND OBJECTIVE: Treatment for adrenal insufficiency (AI) remains suboptimal.
Despite glucocorticoid replacement, patients with AI have reduced life expectancy and …

Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity–data from the EU-AIR

RD Murray, B Ekman, S Uddin, C Marelli… - Clinical …, 2017 - research.rug.nl
Context and objective: Treatment for adrenal insufficiency (AI) remains suboptimal. Despite
glucocorticoid replacement, patients with AI have reduced life expectancy and quality of life …

Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity-data from the EU-AIR

RD Murray, B Ekman, S Uddin… - Clinical …, 2017 - pubmed.ncbi.nlm.nih.gov
Context and objective Treatment for adrenal insufficiency (AI) remains suboptimal. Despite
glucocorticoid replacement, patients with AI have reduced life expectancy and quality of life …